Cannara Biotech (CNSX:LOVE – Get Free Report) has been assigned a $3.00 price objective by stock analysts at Haywood Securities in a note issued to investors on Monday,BayStreet.CA reports. The firm presently has a “buy” rating on the stock.
Separately, TD Securities set a $3.25 price objective on Cannara Biotech and gave the stock a “buy” rating in a report on Tuesday, February 24th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Cannara Biotech has a consensus rating of “Buy” and an average price target of $3.13.
Check Out Our Latest Stock Analysis on Cannara Biotech
Cannara Biotech Stock Performance
Cannara Biotech Company Profile
Cannara Biotech Inc is a vertically integrated cannabis company building the largest indoor cannabis cultivation facility in Quebec, a modern and secure 625,000 square foot facility. Leveraging Quebec’s low electricity costs, Cannara will produce high-grade indoor cannabis, specializing in derivative products and brands.
Further Reading
Receive News & Ratings for Cannara Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cannara Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
